{"url_path":"/sec/dcgo/8-k/2026-07-02/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1822359/0001628280-26-046919-index.html","accession_number":"0001628280-26-046919","cik":"0001822359","ticker":"DCGO","issuer_name":"DocGo Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1822359/0001628280-26-046919-index.html","primary_entity_key":"0001822359","primary_entity_name":"DocGo Inc."},"word_count":355,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn June 26, 2026, the Board of Directors of DocGo Inc. (the “Company”) approved an extension of the expiration date of the Company’s current share repurchase program (“Repurchase Program”) from June 30, 2026 to December 31, 2026. As previously disclosed, pursuant to the Repurchase Program, the Company may purchase up to $26 million in shares of the Company’s common stock. Other than the extension of the program’s expiration date, no changes were made to the Repurchase Program.\n\nUnder the terms of the Repurchase Program, as extended, the Company may continue to purchase shares of its common stock on a discretionary basis from time to time through open market repurchases or privately negotiated transactions or through other means, including by entering into Rule 10b5-1 trading plans or accelerated share repurchase programs, in each case, during an “open window” and when the Company does not possess material non-public information.\n\nThe timing and actual number of shares repurchased under the Repurchase Program will depend on a variety of factors, including stock price, trading volume, market conditions, corporate and regulatory requirements and other general business considerations. The Repurchase Program may be modified, suspended or discontinued at any time without prior notice.\n\nRepurchases under the Repurchase Program may be funded from the Company’s existing cash and cash equivalents, future cash flow or proceeds of borrowings or debt offerings.\n\nThe information in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.\n\n1\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDOCGO INC.\n\nBy:\n\n/s/ Norman Rosenberg\n\nName:\n\nNorman Rosenberg\n\nTitle:\n\nChief Financial Officer and Treasurer\n\nDate: July 2, 2026\n\n2"}